Replies to post #223773 on Biotech Values

[DewDiligence]

Yet another RSV failure (eom).

[DewDiligence]

Re: RSV vaccine from MRK/MRNA

From MRNA’s 1Q19 PR:

https://finance.yahoo.com/news/moderna-reports-first-quarter-2019-110000485.html

Respiratory syncytial virus (RSV) vaccine (mRNA-1777 and mRNA-1172): Merck…plans to run a Phase 1 study for a follow-on development candidate (mRNA-1172), a vaccine for RSV which has shown enhanced potency in preclinical studies and uses a Merck proprietary formulation. As a result, further development of mRNA-1777 has been paused…

h/t @bio_clouseau.

[DewDiligence]

NVAX implements 1:25 reverse split effective at Friday’s open:

https://www.globenewswire.com/news-release/2019/05/08/1819736/0/en/Novavax-Announces-Reverse-Stock-Split-of-Common-Stock.html

[DewDiligence]

NVAX +40%* on new ResVex data:

https://finance.yahoo.com/news/data-novavax-phase-3-prepare-110000990.html

Maybe the recent reverse split (#msg-148698439) has rejuvenated these shares, LOL.

*+50% cumulatively on Tue/Wed.